Serina Therapeutics advances SER-252 Cohort 2 after Cohort 1 review
Serina Therapeutics said an Independent Safety Monitoring Committee recommended advancing SER-252 to Cohort 2 after blinded review of Cohort 1 safety and tolerability data. PK observations at the lowest dose were consistent with sustained apomorphine exposure.
An Independent Safety Monitoring Committee recommended advancing to Cohort 2 after a blinded review of Cohort 1 safety and tolerability data. Pharmacokinetic observations at the lowest dose evaluated were consistent with the sustained apomorphine exposure SER-252 is designed to provide. Blind review of the Cohort 1 data informed the recommendation.